349 results on '"Berraondo, Pedro"'
Search Results
2. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
3. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
4. Intratumoral administration of mRNA encoding IL-12-based immunocytokines targeting CSF1R and PD-L1 exert potent antitumor effects while restraining systemic exposure to IL-12
5. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists and TGF-β antagonists.
6. A human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes
7. Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment
8. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
9. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy
10. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1
11. Unveiling the multifaceted antitumor effects of interleukin 33.
12. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
13. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model
14. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
15. Response to therapy in Richter syndrome: a systematic review with meta-analysis of early clinical trials
16. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis
17. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
18. Druggable Targets in Cytokine Release Syndromes
19. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
20. Cytokines in clinical cancer immunotherapy
21. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria
22. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
23. Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy
24. Repurposing the yellow fever vaccine for intratumoral immunotherapy
25. Silver nanoparticles induce a non-immunogenic tumor cell death.
26. International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain
27. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution
28. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
29. Abstract 614: CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
30. Table_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.xlsx
31. DataSheet_1_Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.pdf
32. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution
33. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models
34. Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment
35. Depletion of Conventional Type-1 Dendritic Cells in Established Tumors Suppresses Immunotherapy Efficacy
36. Editorial: Cytokine and cytokine receptor-based immunotherapies: Updates, controversies, challenges, and future perspectives
37. Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
38. Abstract 3826: A therapeutically actionable pro-tumoral axis of cytokines involving interleukin-8, TNFα and IL-1β
39. A Human IgE bispecific antibody shows potent cytotoxic capacity mediated by monocytes
40. Overexpression of apolipoprotein A-I fused to an anti-transforming growth factor beta peptide modulates the tumorigenicity and immunogenicity of mouse colon cancer cells
41. Revisiting Intracavitary Immunotherapy of Cancer
42. Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies
43. Cancer Immunosurveillance Caught in the Act
44. Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8+ T cells eradicates peritoneal metastases in mouse models.
45. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy
46. Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors
47. Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome
48. Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies
49. Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNγ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice
50. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.